Loading clinical trials...

Tofacitinib Ointment For Chronic Plaque Psoriasis | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Tofacitinib Ointment For Chronic Plaque Psoriasis

A Phase 2b, Multi-site, Randomized, Double-blind, Vehicle-controlled, Parallel-group Study Of The Efficacy, Safety, Local Tolerability And Pharmacokinetics Of 2 Dose Strengths And 2 Regimens Of Tofacitinib Ointment In Subjects With Chronic Plaque Psoriasis.

NCT01831466•Pfizer

View on ClinicalTrials.gov

Summary

The study is beng done to test if tofacitinib ointment is safe and effective for people with plaque psoriasis. Two dose strengths of tofacitinib ointment (20 mg/g and 10 mg/g) applied once or twice daily are being tested. The safety and effectiveness of tofacitinib ointment used for 12 weeks will be compared to the safety and effectiveness of placebo ointment (vehicle) used for 12 weeks.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Have mild, moderate or severe plaque psoriasis (psoriasis vulgaris) for at least 6 months prior to Baseline
•At Baseline, have plaque psoriasis covering 2% to 20% of total body surface area (BSA) on the trunk and limbs (excluding palms, soles, and nails)
•If received certain treatments, should be off treatment for a minimum period of time (washout)

Exclusion Criteria

•Currently have non-plaque forms of psoriasis or drug-induced psoriasis
•Require treatment with or cannot stop medication(s) prohibited during the study
•Have certain laboratory abnormalities at Baseline
•Current or history of certain infections
•Females who are pregnant, breastfeeding, or are of childbearing potential not using highly effective contraception

Locations (54)

Burke Pharmaceutical Research

Hot Springs, Arkansas, United States

Bakersfield Dermatology and Skin Cancer Medical Center

Bakersfield, California, United States

UC Irvine Dermatology Research

Irvine, California, United States

Dermatology Research Associates

Los Angeles, California, United States

Park Avenue Dermatology, PA

Orange Park, Florida, United States

Olympian Clinical Research

Tampa, Florida, United States

Atlanta Dermatology, Vein & Research Center

Alpharetta, Georgia, United States

Advanced Medical Research, Inc

Atlanta, Georgia, United States

MedaPhase Inc.

Newnan, Georgia, United States

Dundee Dermatology

West Dundee, Illinois, United States

Key Dates

Start Date

May 1, 2013

Primary Completion Date

September 1, 2014

Completion Date

September 1, 2014

Last Updated

November 25, 2015

Enrollment

476

ACTUAL participants

Conditions

Psoriasis VulgarisPsoriasis

Interventions

tofacitinib ointment 20 mg/g

DRUG

tofacitinib ointment 10 mg/g

DRUG

placebo ointment (vehicle)

DRUG

tofacitinib ointment 20 mg/g

DRUG

tofacitinib ointment 10 mg/g

DRUG

placebo ointment (vehicle)

DRUG

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

NCT07449234

Psoriasis

View study

RECRUITINGPHASE3

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967

Plaque Psoriasis

View study

RECRUITINGPHASE3

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

NCT07250802

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 25, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Tofacitinib Ointment For Chronic Plaque Psoriasis

Inclusion Criteria

Exclusion Criteria

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

Real-Life Evaluation of Guselkumab Dosing Interval Adjustments